Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"BioSpecifics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"$540.0 million","newsHeadline":"Endo Completes Acquisition of BioSpecifics","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo to Present Qwo\u2122 (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Aesthetics to Introduce New Clinical Study of Qwo\u00ae (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Collagenase Clostridium Histolyticum

    Menu

    Collagenase Clostridium Histolyticum

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Endo International

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

              Details:

              EN3835 (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is being investigated for plantar fibromatosis.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Rare Diseases and Disorders Product Name: EN3835

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo International

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder

              Details:

              Phase 2 study participants receiving up to 3 doses of Xiaflex (collagenase clostridium histolyticum) showed improvement in change from baseline ifor affected shoulder at Day 95, compared to those study participants receiving placebo was not significant.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Musculoskeletal Product Name: Xiaflex

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo International

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

              Details:

              Qwo (collagenase clostridium histolyticum-aaes), is a prescription medicine used to treat moderate to severe cellulite in the buttocks of adult women, may cause serious side effects including allergic.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Dermatology Product Name: Qwo

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioSpecifics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Completes Acquisition of BioSpecifics

              Details:

              BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Urology Product Name: Xiaflex

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Endo Pharm

              Deal Size: $540.0 million Upfront Cash: $540.0 million

              Deal Type: Acquisition December 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo International

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)

              Details:

              Endo International will present data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women during the American Society for Dermatologic Surgery's Annual Meeting.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Dermatology Product Name: Qwo

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo Pharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo to Present Qwo™ (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)

              Details:

              Endo International plc presentation will include a general overview of collagenase clostridium histolyticum-aaes and will review data from the product's phase 3 pooled trial analyses.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Dermatology Product Name: Qwo

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY